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Attention was first drawn to the association
between analgesic abuse and chronic renal damage
by SpUhler and Zollinger in 1950 fIll. Between that
time and 1967, many studies attempted to investigate
the nature of this association, yet none of these were
able to assess quantitatively the extent of the rela-
tionship between excessive use of analgesics and
subsequent development of urorenal disorders. What
seemed to be needed was a longitudinal study in a
healthy population which would incorporate reliable
and valid measurements of analgesic use as well as
urorenal disorders.
With this in mind, an epidemiologic study was
designed in Switzerland using a study population of
apparently healthy women who were 30 to 49 years
of age. A previous investigation had indicated that
heavy intake of analgesics is more prevalent in wom-
en than in men and most prevalent in women of this
age group [21. This study was designed to be con-
ducted in four phases as outlined: Phase I (complet-
ed 1968) was a two-stage screening procedure to
establish a study group of women, aged 30 to 49 yr,
who show evidence of high intake of phenacetin-
containing analgesics and a matched control group of
women who show no such evidence of high intake.
Phase 2 (also completed 1968) was an interview and
examination of both study and control groups, and
phase 3 (completed 1972) was a follow-up of these
women, including yearly examinations from 1969—
72. Phases 1, 2, and 3 have been reported elsewhere
[3, 41. Phase 4 was started in 1975: it consists of
further follow-ups at three-year intervals.
The present report concerns the incidence of uro-
renal disorders in the study and control groups dur-
ing the last follow-up in 1975.
Methods
and control groups were established consisted of
women, aged 30 to 49 yr, employed in various enter-
prises in Northwestern Switzerland. For conve-
nience, the study was limited to the area (3,000 km2)
containing Base!, Baden, Neuchâtel, and Le Lode.
Some 88 establishments agreed to have their employ-
ees participate on a voluntary basis in the study.
These enterprises, employing about 13,000 women,
aged 30 to 49 yr, represented watchmaking, pharma-
ceutical-chemical, metallurgic, textile, food and
tobacco, paper, retailing, banking, and insurance.
First screening. Letters offering a health screening
for detection of kidney disease and/or diabetes melli-
tus were written to women who were aged 30 to 49 yr
and were signed by the management of the establish-
ments. They were not told anything about the
screening for analgesic intake. On the day of the first
contact, one urine sample was collected from each
participating woman by the field team which consist-
ed of a physician, a nurse, and a laboratory techni-
cian. A short questionnaire which asked for the per-
son's name, age, marital status, parity, place of
work, and nationality was completed. Two further
urine specimens spontaneously voided at home on
two different days within a week of the first meeting
were mailed directly to the laboratory. These were
analyzed for the presence of N-acetyl-p-aminophen-
ol (NAPAP), the main metabolite of phenacetin, by
the method of Brodie and Axelrod [51, and speci-
mens showing readings beyond 0.047 optical density
(OD) [61 were considered as positive. If none of the
three specimens submitted was positive by this
criterion, the individual was considered negative. If,
on the other hand, one or more of the three specimens
were positive, the individual was screened further.
Phase 1: Establishment of study and control groups
Population. The population from which the study
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Second screening. All persons who had one or
more specimens positive for NAPAP at the first
screening were summoned at their place of work and
were asked to submit one urine specimen immediate-
ly and to mail two more from home in the successive
two to three days. These three specimens were ana-
lyzed again for NAPAP. Persons having one or more
positive specimens were eligible for the study group.
Study group. This group consisted of 623 individu-
als having one or more specimens positive for
NAPAP at both the first and second screening and
who agreed to participate in the study. For purposes
of analysis, the study group was subdivided into a
high-NAPAP subgroup and a low-NAPAP
subgroup. These subgroups were obtained by aver-
aging the NAPAP concentrations of the screening
urines collected for each individual. Those whose
mean NAPAP readings were under 0.200 OD were
placed in the low-NAPAP subgroup, while those
whose mean readings were 0.200 OD or higher were
placed in the high-NAPAP subgroup.
Control group. For each member of the study
group, a matched control was chosen from the group
of persons who either had no specimen positive for
NAPAP at the first screening or had one or more
positive specimens at the first screening but no addi-
tional specimens positive for NAPAP at the second
screening. A matching was based on: 1) age (within a
five-year range), 2) parity (0 vs. 1 or more), 3)
nationality (Swiss, non-Swiss), 4) marital status, and
5) type of work. Because of difficulties in obtaining
matches, the last three criteria were not always ful-
filled. The results of the matching are shown in a
previous report [3], and the study and control groups
were very similar with respect to many demographic
variables. All women were questioned on their pat-
tern of intake of analgesics, and any woman respond-
ing that she customarily was taking analgesics on two
or more occasions weekly was considered a regular
user of analgesics and was excluded from the control
group. The final control group consisted of 621 rather
than 623 women, owing to an initial loss of two
women who dropped out before the main exam-
ination.
Phase 2: Main examination and interview
Each member of the study group was examined in
1968 during a working day, between 8 and 11 A.M.
Time lost from work was paid for by the employer.
There was no charge for the examination. Examina-
tions were carried out in a private room at the estab-
lishment in which the individual was employed, and
the average examination time was about 20 mm per
person. Each prospective match for a member of the
study group was also examined and included in the
control group if she did not answer "yes" to the
previously mentioned question on analgesic intake.
The following questions and procedures were
included in the examination and interview. 1) Ques-
tions were asked pertaining to analgesic intake, his-
tory of urorenal disease, and smoking history, in
addition to certain questions of demographic, social,
or psychological nature. 2) Serum creatinine values
were obtained by venepuncture and were determined
by an automated method [71. Each year, a frequency
distribution of serum creatinine concentrations was
obtained, and all individuals with readings above the
95th percentile were considered abnormal for this
parameter. 3) Urine was obtained as freshly voided,
clean-catch specimens [81, and was examined by
Labstix® (Ames Company, BRD-6lOl Seeheim, Ger-
many) for blood, protein, and sugar. Protein concen-
trations of 30 mgIlOO ml or more were considered to
be abnormal. 4) Urine cultures were performed with
Urotube® (F. Hoffmann-La Roche & Co. AG, Basel)
at the Institut für Bakteriologie und Hygiene of the
University of Basel, as described elsewhere [91, and
samples with more than l0 colonies per ml were
considered to be abnormal, regardless of bacterial
species. A second urine specimen was obtained, usu-
ally the following morning. Two consecutive positive
specimens showing the same species were used as
criterion for presence of bacteriuria. 5) Each individ-
ual was instructed to thirst overnight (at least 12 hr),
and urine was examined for specific gravity with the
aid of a refractometer (American Optical). Values of
1.010 or less were considered to be abnormal.
Phase 3: Yearly fillow-up examinations (1969—1972)
1) The first three follow-up examinations and
interviews on the job or at home were similar to the
main examination and interview discussed above,
with the exception that all subjective items were
omitted except for questions relating to newly
acquired kidney disorders. 2) In the examination of
1972, questions pertaining to habits of analgesic
intake, fluid intake, and smoking were added.
Phase 4: Three-year follow-up examinations (1975,
prospectively 1978, etc.)
This examination with interview was conducted in
a similar manner to the yearly follow-up examina-
tions from 1969—1971. A psychological investigation
in four parts was added (results to be reported else-
where). The total time for the interview per person
lasted from 20 mm to one hour. This procedure
increased the number of women refusing to collabo-
rate in the fourth phase of the study in 1975.
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Results
Our analysis focused on the incidence during the
course of the follow-up examinations (1969—1972 and
1975) of five conditions considered to be indicative of
possible urorenal disease among those members of
the study and control groups who were free of these
conditions at the initial examination (1968). These
conditions were proteinuria, hematuria, low urine
specific gravity (after thirsting overnight), elevated
serum creatinine concentrations, and bacteriuria.
We restricted our analysis of each of these condi-
tions to those women who were initially negative for
the condition and who were examined for it at all
subsequent examinations. There was a small but
consistent decline in the proportion followed-up at
each examination, with the biggest decline between
follow-up four and five (1972—1975); indeed, out of
1,244 persons present in 1968, 129 (10.4%) were not
examined in 1975. Of these, 26 were dead, and 25
had left Switzerland for a residence abroad. There
were no significant differences in losses to follow-up
between the high-NAPAP and low-NAPAP sub-
group and the control group at any of the follow-
up visits or in the proportion that were present at all
five follow-up examinations. Out of 1,244 persons,
1,081 were present at all five follow-up examinations
(Table 1).
For each condition, Table 2 shows the number and
percentage of persons who were initially negative
and were examined for it at each yearly follow-up
examination. For all conditions, 79 to 88% of those
initially negative were measured each year for the
condition again.
Tables 3 through 7 record the distribution of find-
ings for the five conditions believed to indicate possi-
ble urorenal disease among members of the study
and control groups who were free of these conditions
at the initial examination in 1968.
On the left of the Tables 3—7 are represented the
numbers of abnormal values from 1969—1975, where-
by it was assumed that two or more abnormal values
during the follow-up were evidence of a possible
pathological result. This assessment is a relatively
mild measure for pathological evidence, i.e., evi-
dence for the development of renal disease.
On the far right of Tables 3—7, a more strict and
conservative measure indicating the beginning of
renal disease was used: in members of the study and
control groups initially normal for a specific condi-
tion, the three patterns believed to indicate a patho-
logical result were five consecutive abnormal find-
ings on the yearly 1969—1972 and the 1975
examinations; a normal determination followed by
four abnormal ones; or two normal ones followed by
three abnormal determinations or three normal ones
followed by two abnormals.
Urine-specific gravity after thirsting overnight
(Table 3). If we regard two or more abnormal urine-
specific gravity determinations during follow-up as
evidence of possible concentrating defect, then
17.0% in the study group, as opposed to 5.3% in the
control group, show such evidence. In the high-
NAPAP subgroup, 25.5% had two or more subse-
quent abnormal specific gravity determinations,
while in the low-NAPAP subgroup there were only
9.1%. Both these differences are highly significant.
Turning to the more strict criterion (on the right
hand side of Table 3) of numbers and percent having
a consistent low specific gravity pattern, only 13
women (2.9%) of the total study group had consis-
tently positive findings, as opposed to five persons
(1.0%) in the control group. This difference was not
statistically significant, due probably to the low rate
(1.3%) in the low-NAPAP subgroup. There
was however, a statistically significant difference
between the high-NAPAP subgroup and the control
group.
Serum creatinine (Table 4). In the study group,
5.5% had abnormal levels on two or more follow-up








1969 31 1/316 (0.984) 300/307 (0.977) 606/621 (0.976) 1217/1244 (0.978)
1970 304/316(0.962) 292/307(0.951) 600/621 (0.966) 1196/1244(0.961)
1971 300/316 (0.949) 289/307 (0.941) 587/621 (0.945) 1176/1244 (0.945)
1972 298/316(0.943) 287/307(0.935) 585/621 (0.942) 1170/1244(0.941)
1975 2911V316 (0.918) 265/307 (0.863) 560/621 (0.902) 1115/1244 (0.896)
Present at all 5
follow-up
examinations 277/316 (0.877) 256/307 (0.834) 548/621 (0.882) 1081/1244 (0.869)
Percentages of decline are shown in parentheses.
b NAPAP = N-acetyl-p-aminophenol.
44 Dubach et a!
Table 2. Number of persons in study and control groups initially negative for each condition and measured for it on all five follow-up
examinations
Study group Control group
No. initially No. measured on No. initially No. measured on
negative for all 5 follow-up negative for all 5 follow-up
Condition condition examinations condition examinations
Proteinuria 584 500 (85.6%) 602 529 (87.9%)
Hematuria 612 520 (85.0%) 608 534 (87.8%)
Bacteriuria 594 510 (85.9%) 589 514 (87.3%)
Low urine-specific
gravity (post-thirst) 552 447 (81.0%) 590 506 (85.8%)
Raised serum creatinine 569 452 (79.4%) 579 478 (82.6%)
Table 3. Study and control groups, 1969—1975: Distribution of persons initially normal for urine-specific gravity by number of positive
results on subsequent examinations, and by number having consistent positive patterns of low urine-specific gravity on subsequent
examination
No. of abnormally Iow urine-specific gravity findings, 1969—75
% having two
Two or more No. and % having consistent
or abnormal low urine specific gravity
Group Total None One more findings patterna
Total study group 447 262 109 76 17.0%' 13 (2•9%)f
High-NAPAP
subgroup 216 93 68 55 25.5%' 10 (4.6%)
Low-NAPAP
subgroup 231 169 41 2! 9.1%e 3(1.3%)'
Control group 506 407 72 27 5.3% 5(1.0%)
a A consistent positive pattern on the first five follow-up examinations is either five positive results, a negative followed by four positives,
two negatives followed by three positives, or three negatives followed by two positives.
Study group vs. control group, P < 0.001.
High-NAPAP subgroup vs. low-NAPAP subgroup, P <0.001.
1 High-NAPAP subgroup vs. control group P <0.001.
Low-NAPAP subgroup vs. control group, NS.
'Study group vs. control group, NS.
High-NAPAP vs. low-NAPAP subgroup, NS.
High-NAPAP subgroup vs. control group, P = 0.004.
Low-NAPAP subgroup vs. control group, NS.
Table 4. Study and control groups, 1969—1975: Distribution of persons having initial normal levels of serum creatinine by number of raised
levels on subsequent examinations, and by number having consistent positive patterns
No. of raised serum creatinine findings, 1969—75
% having two
Two or more
or abnormal No. and % with consistent
Group Total None One more findings positive patternsa
Total study group 452 387 40 25 5.5%" 13 (2.9%)'
High-NAPAP subgroup 226 177 27 22 97%c.d 12 (5,3%)g.h
Low-NAPAP subgroup 226 210 13 3 1.3%e 1(0.4%)'
Control group 478 435 39 4 0.8% 0 (0%)
a A consistent positive pattern is defined as in Table 3.
b Study group vs. control group, P <0.001.
High-NAPAP subgroup vs. low-NAPAP subgroup, P <0.001.
d High-NAPAP subgroup vs. control group, P <0.001.
Low-NAPAP subgroup vs. control group, NS.
'Study group vs. control group, P <0.001.
High-NAPAP subgroup vs. low-NAPAP subgroup, P = 0.005.
High-NAPAP subgroup vs. control group, P <0.001.
'Low-NAPAP subgroup vs. control group, NS.
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examinations, whereas among comparable members
of the control group, only 0.8% had abnormal creati-
nine levels on two or more occasions during the
follow-up period—a highly significant difference! Of
the 25 members of the study roup who had normal
serum creatinine levels in 1968 and had two or more
abnormal levels during the follow-up period, 22 were
in the high-NAPAP subgroup. In fact, 9.7% of those
members of this subgroup had two or more abnormal
serum creatinine results among their 1969— 1972 and
1975 follow-up determinations. This contrasted with
the finding of 1.3% among comparable members of
the low-NAPAP subgroups; the difference between
the two subgroups was highly significant.
Table 4 also presents the findings on consistent
positive patterns of raised serum creatinine concen-
trations, as defined above. The percentage with such
patterns was 2.9% among members of the study
group, as opposed to 0% among comparable mem-
bers of the control group (P < 0.001). The bulk of
these abnormal positive patterns for raised serum
creatinine values were concentrated in the high-
NAPAP subgroup, with 5.3% having consistently
positive findings as opposed to 0.4% among mem-
bers of the low-NAPAP subgroup (P = 0.005).
Bacteriuria (Table 5). Whereas statistical analysis
after four years of follow-up in 1972 [41 showed no
significant differences between the study and control
groups on either criterion, there was, after the fifth
follow-up, some slight evidence for statistical signifi-
cance emerging for the criterion of two or more
positives, whereas for the strict criterion (right hand
side of Table 4) only six women were positive in the
total study group vs. five women in the control
group, and therefore no statistical significance was
obtained. The less severe measure of two and more
abnormal findings between 1968 and 1975 revealed a
slight difference in the number of positive persons in
the total study group, with 29 (5.7%) vs. the 17
persons (3.3%) in the control group. Although these
values were not statistically different, the breakdown
of the study group showed significant differences
between the high and low-NAPAP subgroups, with
22 (8.4%) and 7 (2.8%) positive persons, respectively(P = 0.012). Also, the high-NAPAP subgroup had
statistically higher rates than the control group (P =
0.004).
Hematuria (Table 6). There was no statistical dif-
ference between the total study group and the con-
trol group; indeed the control group showed more
pathological results than the study group on both
criteria.
Proteinuria (Table 7). The numbers were very
small, and no difference was found between the total
study group and the control group. No women
showed a consistent positive pattern for proteinuria
in either group.
Discussion
Astonishingly enough, only two major epidemio-
logical studies on the use of analgesics and the
development of urorenal disease have appeared in
the literature [10, 111. A study conducted by the
Boston Collaborative Drug Surveillance Program
(BCDSP) screened a sample of 6,407 consecutive
hospital admissions for history of analgesic abuse
and found no relationship between frequency of anal-
gesic use and evidence of urorenal disease, as mea-
Table 5. Study and control groups, 1969—1975: Distribution of persons initially normal for bacteriuria by number of positive results in
subsequent examinations and by number having consistent positive patterns of bacteriuria on subsequent examinations
No. of abnormal bacteriuna findings, 1969—75
% having two
Two or more
or abnormal No. and % having consistent
Group Total None One more findings positive patterns"
Total study group 510 410 71 • 29 57%b 6 (l.2%)f
High-NAPAP subgroup 263 195 46 22 8.4% 5 (19%)g.h
Low-NAPAP subgroup 247 215 25 7 2.8%e 1 (0.4%)'
Control group 514 429 68 17 3.3% 5 (1.0%)
"A consistent positive pattern is defined as in Table 3.
b Study group vs. control group, NS.
High-NAPAP subgroup vs. low-NAPAP subgroup, P = 0.012.
High-NAPAP subgroup vs. control group, P = 0.004.
Low-NAPAP subgroup vs. control group, NS.
Study group vs. control group, NS.
High-NAPAP subgroup vs. low-NAPAP subgroup, NS.h High-NAPAP subgroup vs. control group, NS.
Low-NAPAP subgroup vs. control group, NS.
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Table 6. Study and control groups, 1969—1975: Distribution of persons initially normal for hematuria by number of positive results on
subsequent examinations and by number having consistent positive patterns of hematuria on subsequent examinations
No. of abnormal hematuna findings 1969—75
% having two
Two or more
or abnormal No. and % having consistent
Group Total None One more findings hematuria patternsa
Total study group 520 470 42 8 1 5%5 2 (0.4%)
High-NAPAP subgroup 272 244 23 5 1.8%" 0 (O%)s5
Low-NAPAP subgroup 248 226 19 3 1.2%e 2(0.8%)'
Control group 534 480 41 13 2.4% 4(0.7%)
A consistent positive pattern is defined as in Table 3.
b Study group vs. control group, NS.
High-NAPAP subgroup vs. low-NAPAP subgroup, NS.
High-NAPAP subgroup vs. control group, NS.
Low-NAPAP subgroup vs. control group, NS.
'Study group vs. control group, NS.
High-NAPAP subgroup vs. low-NAPAP subgroup, NS.h High-NAPAP subgroup vs. control group, NS.
Low-NAPAP subgroup vs. control group, NS.
Table 7. Study and control groups, 1969—1975: Distribution of persons initially normal for proteinuria by number of positive results cn
subsequent examinations, and by number having consistent positive patterns of proteinuria on subsequent examinations
No. of abnormal proteinuria findings, 1969—75
% having two
Two or more
or abnormal No. and % having consistent
Group Total None One more findings proteinuria patterna
Total study group 500 459 33 8 1.6%" 0 (0%)
High-NAPAP subgroup 259 234 19 6 2.3%'" 0 (0%)
Low-NAPAP subgroup 241 225 14 2 0.8%' 0 (0%)
Control group 529 494 29 6 1.1% 0 (0%)
a A consistent positive pattern is defined in Table 3.
Study group vs. control group, NS.
High-NAPAP subgroup vs. low-NAPAP subgroup, NS.
High-NAPAP subgroup vs. control group, NS.
Low-NAPAP subgroup vs. control group, NS.
sured by mean blood urea nitrogen (BUN) values
and discharge diagnosis of renal disease [111!. Simi-
larly, a community survey of 3,000 women in a
Welsh industrial valley found that women who
admitted to taking more than four analgesic pills
daily showed no evidence of having significantly
higher prevalences of abnormal BUN or serum cre-
atinine for concentrating deficiency than those who
used analgesics less frequently or not at all [10].
Differences in the findings among the two studies and
the Swiss study could be attributed to differences in
study designs and methods employed. The BCDSP
used a hospitalized population, whereas the Welsh
study was a community survey. Both studies deter-
mined analgesic intake by history-taking, and neither
focused primarily on phenacetin-containing analge-
sics. While the BCDSP had a large group of analgesic
users, the Welsh study had only 50 persons with
heavy analgesic intake.
The Swiss study (although essentially a volunteer
study), in contrast with the BCDSP and Welsh sur-
veys, was a true longitudinal investigation in a work-
ing, healthy middle-aged population numbering 1,244
women in 88 enterprises. Switzerland was chosen for
this type of investigation because previous investiga-
tions have indicated that it has a large population
with marked abuse of analgesics. In addition, most
leading brands of analgesics marketed in Switzerland
contain phenacetin, whereas salicylates are used to a
much lesser extent in analgesic mixtures. The study
used laboratory methods in screening for intake of
phenacetin-containing pills, and presence, as defined
above, of its main metabolite NAPAP was taken as
the most expedient indicator of regular intake of
analgesics.
The purity of both study and control groups has
been evaluated both by use of an independent ques-
tion concerning the type of analgesic used [311 and by
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use of a mathematical model fitted to the data [121.
Approximately 75% of the study group stated that
they used brands of analgesics containing phenace-
tin, whereas only about 24% of the control group
stated that they used these brands. The mathematical
model estimated that 46% of the study group, as
opposed to 4% of the control group, took the equiva-
lent of 250 mg of phenacetin every day. The likely
heterogeneity of the study group with respect to
intake of analgesics had been recognized, and all
results in the study group have been presented sepa-
rately for the two subgroups which represent low and
high analgesic intake, as measured by average
NAPAP levels in the urines collected during the 1968
screening program.
To assess by laboratory methods early urorenal
disease in an apparently healthy population under
field conditions remains difficult. For the five param-
eters studied (proteinuria, hematuria, bacteriuria,
low specific gravity after thirst overnight, and elevat-
ed serum creatinine concentrations), the present
paper focuses on those initially (1968) negative for
the condition and measured for it at each follow-
up examination (1969—1972, 1975). This procedure
seems justified to us by the fact that for each condi-
tion 79.4 to 87.9% (Table 2) of those persons initially
negative were examined at each of the five subse-
quent examinations. The follow-up loss of the 623
members of the study group and of the 621 members
of the control group was very small, with 10.4% over
the seven calendar years (Table 1).
NAPAP is the most important metabolite of phen-
acetin, since 64 to 89% of an oral dose of phenacetin
is excreted in the urine as NAPAP [13]. A result of
more than 0.047 OD NAPAP in a casual sample of
urine is considered indicative of ingestion of at least
one pill of a phenacetin-containing analgesic. With
casual samples, only about 50% of persons tested at
random within 12 hr after taking one pill containing
250 mg of phenacetin are likely to be positive for
NAPAP by this criterion. Levels of NAPAP greater
than 0.200 OD in casual samples are indicative of
heavier intake and might be found in persons taking
at least five tablets containing 250 mg of phenacetin
each within 12 hr prior to collection.
Thus, while our screening criteria for selecting the
study and control groups and the high-and low-intake
subgroups are subject to problems of sensitivity and
specificity, we feel that they are justified by previous
studies, and that the screening procedure has given
us a control group consisting of essentially nonusers,
a low-intake subgroup of low to moderate users, and
a high-intake subgroup of essentially heavy users.
Urine concentration studies after thirst have prov-
en to be a most sensitive clinical test for indicating
impaired renal function in patients taking large quan-
tities of phenacetin-containing analgesics, especially
in closely supervised hospital populations [14, 151.
The validity and reliability of this method, however,
under the field conditions of the present study is
subject to some scrutiny. It might be argued that
analgesic abusers might be tense, unstable, and
hence, more likely to break their thirsting period
prematurely. Although this statement cannot be dis-
missed, it is weakened by the fact that the incidence
data is for those who had normal urine specific gravi-
ties in 1968 and, hence, were able to follow the
thirsting procedure at that time. Further analyses
have divided those persons who had normal urine
specific gravity in 1968 into four groups according to
their 1968 levels (1.011 to 1.015, 1.016 to 1.020, 1.021
to 1.025, and 1.026 and over). In each of these
groups, the study group showed greater decrease in
urine specific gravity by time than the control group
[16].
In the seven years of follow-up, mortality with 26
persons dead was higher than the expected 19 deaths
according to a comparative Swiss population. The
difference is only of borderline significance (P <
0.05). Five persons died in the control group, 14 in
the high-NAPAP, and 7 in the low-NAPAP sub-
group. In the high-NAPAP subgroup there was
one death from uremia due to interstitial nephritis,
one due to chronic pyelonephritis, and one due to
urothelcarcinoma of the bladder No urorenal deaths
were recorded in the low-NAPAP subgroup nor in
the control group. Total morbidity as judged by con-
sistent patterns of low specific gravity (study group,
2.9%; control group, 1.0%), of elevated serum creati-
nine concentrations (study group, 2.9%; control
group, 0%), and of bacteriuria (study group, 1.2%;
control group, 1.0%) was low after seven years.
The main result of the Swiss study, so far, lies in
the statistically significant difference for three of the
five conditions studied between the study and con-
trol groups. Likewise, within the study group, the
high-NAPAP subgroup had a higher incidence of
each condition than the low-NAPAP subgroup. The
differences between the two subgroups were espe-
cially striking in their respective incidences of elevat-
ed serum creatinine concentrations, with the high-
NAPAP subgroup having a 5.3% incidence of posi-
tive patterns of elevated serum creatinine values as
opposed to a 0% incidence in the low-NAPAP
subgroup. The incidence in the low-NAPAP sub-
group was similar (0.4%) as that in the control
group. This is consistent with findings by Dubach
and Raaflaub [171 that phenacetin when ingested at
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high oral doses is metabolized into potentially toxic
substances at a much higher rate than when ingested
at low doses. Our analysis after the first four years of
follow-up [4] showed nearly identical incidences for
all groups as after the fifth follow-up in 1975; this
result indicates that most persons who were consis-
tently positive on the 1st four follow-up exams (1969
to 1972) remained positive on the 5th follow-up exam
(1975).
Since the last analysis after four follow-ups in 1972
[4], bacteriuria (Table 5) is showing for the first time
significance for the high-NAPAP subgroup vs. the
control group (P = 0.004); for the two subgroups this
statement is true also. The significance is available
only for one criterion, where two or more findings
must be abnormal in all five follow-ups; the analysis
of numbers having a consistent positive pattern
reveals no such significance due to vety small num-
bers. This may simply reflect the fact that it is harder
to get an accurate bacteriuria measurement, since
there is more variability in the measurement than for
serum creatinine or specific gravity. It is well known
that the turnover rate for bacteriuria (the number of
persons who are positive on one examination and
then negative on a second one) is quite high. Accord-
ing to clinical observation, bacterial infection follows
medullary damage as expected in so-called analgesic
nephropathy. A further follow-up examination (1978)
might help to clarify the pathogenesis of infection in
analgesic nephropathy!
The Swiss study does not attempt and it is unlikely
that any other epidemiological investigation will be
able to unravel a causal relationship between inges-
tion of phenacetin and subsequent development of
urorenal disorders, as phenacetin is rarely ingested
alone as an analgesic.
If analgesic mixtures containing phenacetin do
cause renal damage, it appears most important to
determine the extent of the problem because of its
public health interest. We feel the results of the
Swiss study indicate that high users of analgesic
mixtures (as represented by the high-NAPAP
subgroup) do have a higher incidence of abnormal
kidney function than casual users (as represented by
the low-NAPAP subgroup) and nonusers (as repre-
sented by the control group), but that the absolute
incidence over seven years remains small even
among high users. Prolongation of this study is
planned and is necessary in order to gain an assess-
ment of longer term risk for morbidity and mortality.
Summary
A study group of originally 623 employed women
of Northwestern Switzerland who were aged 30 to 49
yr and showing objective evidence of intake of phen-
acetin-containing analgesics, and a control group of
621 comparable women showing no such intake,
were examined in 1968 and followed-up five times
from 1969 to 1975 for laboratory evidence of urorenal
disorders. Mortality was higher in the study group,
with 21 deaths, compared to the control group, with
5 deaths, and was higher than expected in a compar-
ative population in Switzerland (P 0.05). In both
study and control groups, morbidity was low. There
was no difference between the study and control
groups with respect to subsequent proteinuria and
hematuria. The seven-year incidence of low urine
specific gravity after overnight thirsting was higher in
the study group than in the control group (2.9% vs.
1.0%), and the incidence of raised serum creatinine
was also significantly higher in the study group (2.9%
vs. 0%). However, when the study group was further
subdivided into a subgroup showing evidence of high
intake of phenacetin-containing analgesics and one
showing low-intake, only the high-intake subgroup
had an incidence of raised serum creatinine concen-
trations (5.3%), significantly higher than the control
group (0%), whereas the low-intake subgroup had an
incidence (0.4%) similar to the control group. Also
the high-intake subgroup showed significantly higher
rates of bacteriuria than the controls (P 0.004).
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